Evotec jumps into biologics through $90m Just.Bio acquisition

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/Kkolosov)
(Image: Getty/Kkolosov)

Related tags: Evotec, Biotherapeutics, acquisition, CDMO

Evotec to join the emerging biologics market through Just Biotherapeutics’ smart technology platforms, machine learning tools and low cost manufacturing facilities.

The German drug developer signed a definitive agreement according to which it will offer up to $90m (€80.45m) in cash, including potential performance-based earn-out components expected within the next three years, to the shareholders of Just Biotherapeutics (Just.Bio).

Specifically, the offer is addressed to a syndicate of institutional investors of ARCH Venture Partners, Merck & Co., Lilly Asia Ventures and the Bill & Melinda Gates Foundation.

Just.Bio, a Seattle-based biologics contract development and manufacturing organization (CDMO) founded in 2014, owns J.Design, an integrated platform that consists of:

- J.Mdtm, a computer-aided tool enabling selection of the best molecules for development,
- J.P3, an early clinical manufacturing facility and
- J.Pod, a technology that allows modular larger scale manufacturing of clinical and commercial stage biologics.

A spokesperson of Evotec told us that the company plans to further invest in expanding Just.Bio’s activity and facilities in the US.

“Broadening our platform into biologics has always been key to our strategy,”​ Evotec’s CEO Werner Lanthaler said in a statement.

“With this acquisition we finally found the perfect match to complement our leadership in small molecules,”​ he added.

James Thomas, CEO of Just.Bio will become the global head of biotherapeutics and president of US operations at Evotec and all of Just.Bio's employees will join Evotec's team.

The acquisition is expected to be completed by August 2019.

Related news

Related products

show more

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 06-Dec-2022 | Product Brochure

Your biologics possess a high level of complexities and technical challenges. That’s why development is key to ensuring the successful delivery of your...

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Related suppliers

Follow us


View more